Seeking Alpha
11 Jun 2026, 07:22 UTC · 22w ago
Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026
Impact · against what's priced in
IDYA is positive as the company hits a primary clinical endpoint for darovasertib in HLA*A2-negative mUM and establishes a clear regulatory path toward an NDA filing in H2 2026. These milestones increase the probability of commercialization and expand the potential addressable market.
- IDYA+0.70
No priced-in read yet





